The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
 
Michiel Simon Van Der Heijden
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Gilead Sciences; Merck; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Apogepha; Astellas Pharma; Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Janssen; Merck/Pfizer; MSD
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Ferring; Janssen; Kissei Pharmaceutical; Kyorin; Kyowa Kirin International; Merck; MSD; Nippon Kayaku; Nippon Shinyaku; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ronald De Wit
Consulting or Advisory Role - Astellas Pharma; Bayer; Hengrui Medicine; Orion
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Abbvie; Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Ignacio Duran
Honoraria - Astellas Pharma; AstraZeneca Spain; Bayer/Onyx; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Immunomedics; Janssen Oncology; MSD Oncology; Novartis; Pfizer/EMD Serono; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer; Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca Spain; Bayer/Onyx; Gilead Sciences; Ipsen; Pfizer/EMD Serono; Roche/Genentech
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Margitta Retz
No Relationships to Disclose
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Gilead Sciences; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Gilead Sciences; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); EMD Serono (Inst); Foundation Medicine; Genentech; Genentech; Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Gopa Iyer
Consulting or Advisory Role - Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Merck Sharp & Dohme LLC (Inst)
 
Wen-Pin Su
No Relationships to Disclose
 
Hema Parmar
Employment - Frontier Medicines (I); Seagen
Stock and Other Ownership Interests - Frontier Medicines (I); Seagen
Research Funding - Frontier Medicines (I)
Patents, Royalties, Other Intellectual Property - Patent Number: 11339213 Title: Methods and compositions for treatment of cancer
Travel, Accommodations, Expenses - Seagen
 
Xuesong Guan
Employment - Mirati Therapeutics; Seagen; Zentalis (I)
Stock and Other Ownership Interests - Amgen; Seagn; Zentalis (I)
 
Seema Rao Gorla
Employment - Astellas Pharma
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Begoña Pérez Valderrama
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EUSA Pharma; Merck; Merck/Pfizer; Pfizer; Roche
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis
Travel, Accommodations, Expenses - Merck/Pfizer